AC
EBS icon

Aristeia Capital’s Emergent Biosolutions EBS Stock Holding History

Aristeia Capital’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Buy
+161,753
New +$1.35M 0.02% 299
2026
Q1 		– Sell
-27,949
Closed -$345K – 728
2025
Q4 		$345K Buy
+27,949
New +$299K 0.01% 373
2025
Q3 		– Sell
-149,697
Closed -$955K – 561
2025
Q2 		$955K Buy
+149,697
New +$857K 0.03% 168
2025
Q1 		– Sell
-40,171
Closed -$384K – 456
2024
Q4 		$384K Buy
+40,171
New +$369K 0.01% 219
2024
Q3 		– Sell
-94,163
Closed -$642K – 399
2024
Q2 		$642K Sell
94,163
-50,625
-35% -$218K 0.01% 121
2024
Q1 		$366K Buy
+144,788
New +$326K 0.01% 133

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Aristeia Capital's EBS Position: Q2 2026 in Review

Aristeia Capital opened a new position in Emergent Biosolutions (EBS) in Q2 2026: 161,753 shares worth $1.36M. The stake represents 0.02% of the portfolio and ranks #299 among its holdings. This is a return to the name: Aristeia Capital previously reported a position in EBS as recently as Q4 2025.

Aristeia Capital first reported a position in EBS in Q1 2024 and has held it in 6 quarters since. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Aristeia Capital held 161,753 shares of Emergent Biosolutions worth $1.36M as of Q2 2026.
  • Emergent Biosolutions was a new Aristeia Capital position in Q2 2026.
  • Emergent Biosolutions made up 0.02% of Aristeia Capital's portfolio in Q2 2026, its #299 holding.
  • Aristeia Capital first reported a position in Emergent Biosolutions in Q1 2024 and has held it in 6 quarters since.
  • 195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Aristeia Capital's 13F filing for Q2 2026, filed 14 Aug 2026.